India, June 12 -- image credit- shutterstock

Hyderabad-based Bharat Biotech International Limited (BBIL) has partnered with GSK plc for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3.

The agreement marks a critical step in the advancement of this promising vaccine, targeting Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries.

The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-m...